Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.

McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, Greenlee S, Valderrama A, Sullivan SD, Ramsey SD.

Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.

PMID:
26865591
2.

Use of hypofractionated post-mastectomy radiotherapy reduces health costs by over $2000 per patient: An Australian perspective.

Mortimer JW, McLachlan CS, Hansen CJ, Assareh H, Last A, McKay MJ, Shakespeare TP.

J Med Imaging Radiat Oncol. 2016 Feb;60(1):146-53. doi: 10.1111/1754-9485.12405. Epub 2015 Oct 29.

PMID:
26511607
3.

Tumor marker usage and medical care costs among older early-stage breast cancer survivors.

Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL.

J Clin Oncol. 2015 Jan 10;33(2):149-55. doi: 10.1200/JCO.2014.55.5409. Epub 2014 Oct 20.

4.

Augmented meaningful use criteria to identify patients eligible for lung cancer screening.

Raz DJ, Dunham R, Tiep B, Sandoval A, Grannis F, Rotter A, Kim JY.

Ann Thorac Surg. 2014 Sep;98(3):996-1002. doi: 10.1016/j.athoracsur.2014.04.105. Epub 2014 Jul 23.

PMID:
25063304
5.

The PACT study protocol: a time series study investigating the impact, acceptability and cost of an integrated model for psychosocial screening, care and treatment of patients with urological and head and neck cancers.

Girgis A, Kelly B, Boyes A, Haas M, Viney R, Descallar J, Candler H, Bellamy D, Proietto A.

BMJ Open. 2014 Jan 9;4(1):e004147. doi: 10.1136/bmjopen-2013-004147.

6.

The burden of depression in prostate cancer.

Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ.

Psychooncology. 2012 Dec;21(12):1338-45. doi: 10.1002/pon.2032. Epub 2011 Aug 12.

PMID:
21837637
7.

Projections of the cost of cancer care in the United States: 2010-2020.

Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML.

J Natl Cancer Inst. 2011 Jan 19;103(2):117-28. doi: 10.1093/jnci/djq495. Epub 2011 Jan 12. Erratum in: J Natl Cancer Inst. 2011 Apr 20;103(8):699.

8.

Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer.

Bós AM, Howard BV, Beresford SA, Urban N, Tinker LF, Waters H, Bós AJ, Chlebowski R, Ennis JM.

J Am Diet Assoc. 2011 Jan;111(1):56-66. doi: 10.1016/j.jada.2010.10.011.

9.

Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD.

J Natl Cancer Inst. 2009 Apr 15;101(8):571-80. doi: 10.1093/jnci/djp039. Epub 2009 Apr 7.

10.

Hospitalizations for infection in cancer patients: impact of an aging population.

Cooksley CD, Avritscher EB, Rolston KV, Elting LS.

Support Care Cancer. 2009 May;17(5):547-54. doi: 10.1007/s00520-008-0520-3. Epub 2008 Nov 4.

PMID:
18982364
11.

The utility and cost effectiveness of preoperative computed tomography for patients with uterine malignancies.

Bansal N, Herzog TJ, Brunner-Brown A, Wethington SL, Cohen CJ, Burke WM, Wright JD.

Gynecol Oncol. 2008 Nov;111(2):208-12. doi: 10.1016/j.ygyno.2008.08.001. Epub 2008 Sep 11.

12.

Economic factors affecting head and neck reconstructive microsurgery: the surgeons' and hospital's perspective.

Deleyiannis FW, Porter AC.

Plast Reconstr Surg. 2007 Jul;120(1):157-65.

PMID:
17572558
13.

Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.

Wolf MS, Fitzner KA, Powell EF, McCaffrey KR, Pickard AS, McKoy JM, Lindenberg J, Schumock GT, Carson KR, Ferreira MR, Dolan NC, Bennett CL.

J Clin Oncol. 2005 Dec 1;23(34):8877-83.

14.

Resource utilization for ovarian cancer patients at the end of life: how much is too much?

Lewin SN, Buttin BM, Powell MA, Gibb RK, Rader JS, Mutch DG, Herzog TJ.

Gynecol Oncol. 2005 Nov;99(2):261-6. Epub 2005 Sep 2.

PMID:
16140364
15.

Cost of illness associated with metastatic breast cancer.

Rao S, Kubisiak J, Gilden D.

Breast Cancer Res Treat. 2004 Jan;83(1):25-32.

PMID:
14997052
16.

Incremental treatment costs in national cancer institute-sponsored clinical trials.

Goldman DP, Berry SH, McCabe MS, Kilgore ML, Potosky AL, Schoenbaum ML, Schonlau M, Weeks JC, Kaplan R, Escarce JJ.

JAMA. 2003 Jun 11;289(22):2970-7.

PMID:
12799405
17.

Estimating health care costs related to cancer treatment from SEER-Medicare data.

Brown ML, Riley GF, Schussler N, Etzioni R.

Med Care. 2002 Aug;40(8 Suppl):IV-104-17.

PMID:
12187175
18.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF.

Med Care. 2002 Aug;40(8 Suppl):IV-3-18.

PMID:
12187163
19.

Follow-up among women with an abnormal mammogram in an HMO: is it complete, timely, and efficient?

Burack RC, Simon MS, Stano M, George J, Coombs J.

Am J Manag Care. 2000 Oct;6(10):1102-13.

20.

Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.

Penberthy L, Retchin SM, McDonald MK, McClish DK, Desch CE, Riley GF, Smith TJ, Hillner BE, Newschaffer CJ.

Health Care Manag Sci. 1999 Jul;2(3):149-60.

PMID:
10934539
Items per page

Supplemental Content

Loading ...
Write to the Help Desk